Purpose
To determine the safety and efficacy of combining adenosine (70 mcg/kg/min for 3 h) with one of the thrombolytic agents, either
streptokinase or tissue plasminogen activator (tPA), to further reduce the injury associated with AMI or heart failure
References
The trial design has not been published
|
Farmacêutica